David G. Maloney, MD, PhD
Scientific Advisory Board Member
Professor, Clinical Research Division, Fred Hutch; Medical Director, Cellular Immunotherapy, Fred Hutch; Medical Director Cellular Immunotherapy, Bezos Family Immunotherapy Clinic, Seattle Cancer Care Alliance; Klorfine Endowed Chair for Clinical Research, Fred Hutch; Professor, Division of Medical Oncology, University of Washington. MD and PhD in Cancer Biology from Stanford. David was instrumental in the development and clinical trials of the drug Rituximab, the first antibody-based cancer treatment, and was a member of the team that created the mini-transplant, a less intense form of the conventional allogeneic stem cell transplant. He is currently involved in the development and clinical testing of genetically engineered immune cell therapies (such as CAR-T and others) to treat a variety of cancers. Immune cell therapies are showing huge promise with 5 such therapies FDA approved in the last 4 years. David is a widely recognized expert in translating research into transformational patient outcomes, particularly for those patients with critically unmet needs.